A single-arm phase II trial of gemcitabine, oxaliplatin, and panitumumab in KRAS wild-type advanced biliary tract cancer.
Marcus Smith Noel
No relevant relationships to disclose
Jill N. Allen
No relevant relationships to disclose
Thomas Adam Abrams
No relevant relationships to disclose
Matthew Yurgelun
No relevant relationships to disclose
Jason Edward Faris
Consultant or Advisory Role - N-of-One
Lipika Goyal
No relevant relationships to disclose
Jeffrey W. Clark
No relevant relationships to disclose
Lawrence Scott Blaszkowsky
No relevant relationships to disclose
Janet E. Murphy
No relevant relationships to disclose
Hui Zheng
No relevant relationships to disclose
Alok A. Khorana
No relevant relationships to disclose
Gregory Clayton Connolly
No relevant relationships to disclose
Ollivier Hyrien
No relevant relationships to disclose
Kimmie Ng
No relevant relationships to disclose
Darrell R. Borger
No relevant relationships to disclose
Anthony John Iafrate
No relevant relationships to disclose
Aram F. Hezel
Consultant or Advisory Role - Amgen; Bayer
Andrew X. Zhu
No relevant relationships to disclose